Zai Lab Limited — FY2017 Form 20-F
Reporting period: Fiscal year ended December 31, 2017. Although the request identifies 2017 Q4, this is an annual report; the supplied filing does not provide a standalone fourth-quarter financial breakdown. Financial statements are prepared under U.S. GAAP and audited by Deloitte.
Business context
Zai Lab is a Shanghai-based, clinical-stage biopharmaceutical company developing and licensing treatments for oncology, autoimmune and infectious diseases, primarily for China and selected other markets. It reported no product revenue. Its lead candidate, ZL-2306 (niraparib), was approved in the United States and European Union in 2017 and commercialized there by its partner, Tesaro; Zai Lab was still pursuing China development and planned Hong Kong commercialization in the second half of 2018.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $39.3 million | $32.1 million |
| General and administrative expense | $12.0 million | $6.4 million |
| Operating loss | $51.4 million | $38.5 million |
| Net loss | $50.4 million | $37.5 million |
| Basic and diluted loss per share | $2.32 | $3.97 |
| Cash used in operating activities | $32.4 million | $32.2 million |
| Cash used in investing activities | $10.4 million | $2.7 million |
| Cash provided by financing activities | $187.9 million | $106.2 million |
At year-end, cash and cash equivalents were $229.7 million, total assets were $249.6 million, total liabilities were $14.5 million, and shareholders’ equity was $235.2 million. The filing reports no product revenue, so gross profit and operating margins are not meaningful. No borrowing or debt balance is identified in the supplied financial statements. Management said year-end cash was expected to fund operating and capital needs for at least 12 months, subject to assumptions that could prove incorrect.
R&D expense rose about 22% year over year, driven principally by higher CRO/CMO spending, personnel and other operating costs; licensing fees fell from $17.1 million to $8.0 million. G&A expense increased about 89%, mainly due to personnel and public-company costs. The company reported an accumulated deficit of $110.6 million. FY2017 financing included approximately $157.7 million of net IPO proceeds; preferred shares also converted to ordinary shares upon the IPO.
Material changes versus prior period
- Net loss increased from $37.5 million to $50.4 million, while operating loss increased from $38.5 million to $51.4 million.
- Operating cash use was broadly stable year over year, while investing cash use rose with manufacturing-facility construction and other investment.
- Cash increased to $229.7 million from $83.9 million, primarily reflecting financing proceeds. Total shareholders’ equity moved from a $51.6 million deficit to $235.2 million of equity, including the IPO and conversion of preferred shares.
- Headcount increased to 88 from 50. Zai Lab completed a small-molecule facility and was building a large-molecule facility; completion was expected in the first half of 2018.
Outlook, commentary and risks
- Management expected expenses to rise as it advanced six clinical-stage candidates, developed preclinical programs, pursued trials and approvals, and built manufacturing and commercialization capabilities. The company had not demonstrated profitability and expected continued losses.
- Key development items included ZL-2306 Phase III ovarian-cancer studies in China; a Phase II study of ZL-2301 in advanced liver cancer, with a potential Phase III planned subject to results; and China development planning for ZL-2401. These were plans and expectations, not assured outcomes.
- ZL-2301 had failed primary endpoints in two prior Phase III trials conducted by Bristol-Myers Squibb. Zai Lab believed further China trials were warranted, but success was uncertain. The filing’s descriptions of whether enrollment in its Phase II study was complete are not consistent.
- The company depends on clinical and regulatory success, third-party licensors, CROs and manufacturers, and its ability to obtain additional capital. Licensing agreements may require substantial future milestone payments and royalties; the filing estimates up to approximately $400.8 million in aggregate future milestone payments across agreements, contingent on specified events.
- Other material risks include clinical-trial delays or adverse safety findings; evolving Chinese drug regulation and the 2018 regulatory-agency restructuring; manufacturing scale-up and approval; competition; pricing and reimbursement; intellectual-property disputes; foreign-exchange controls and limits on moving cash from China; and the possibility of further control deficiencies.
- A prior material weakness in financial-reporting controls—insufficient U.S. GAAP/SEC reporting expertise and procedures—was reported as remediated by year-end 2017. Management had not yet provided a Section 404 assessment in this filing, and the auditor did not attest to internal-control effectiveness.
- No material legal proceedings were reported. The company had never paid dividends and did not expect to do so in the near term. Ordinary operating lease, purchase and investment commitments totaled approximately $10.0 million at year-end, excluding contingent licensing milestones and royalties.
Important facts for investors to verify
- Progress, enrollment, endpoints, safety and regulatory timelines for ZL-2306 and other lead candidates; reconcile the filing’s inconsistent ZL-2301 enrollment statements.
- Actual cash burn, facility spending, cash availability in relevant jurisdictions, and whether the stated 12-month funding outlook remains adequate.
- Terms, timing and probability of contingent licensing milestones and royalties, including the disclosed potential aggregate milestone exposure.
- Manufacturing-facility completion, regulatory readiness, and the company’s plans and costs for commercialization, pricing and reimbursement.
- Ongoing effectiveness of financial-reporting controls and the impact of China’s regulatory restructuring and foreign-exchange restrictions.